For Immediate Release
Chicago, IL – November 11, 2010 – Zacks.com Analyst Blog features: Alnylam Pharmaceuticals Inc. (ALNY), Roche (RHHBY), Novartis (NVS), Cubist Pharmaceuticals Inc. (CBST) and Biogen Idec Inc. (BIIB).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Loss at ALNY Lower Than Expected
Alnylam Pharmaceuticals Inc.’s (ALNY) third quarter loss of 23 cents per share was narrower than the Zacks Consensus Estimate of 39 cents but wider than the year-ago loss of 22 cents per share. The wider loss in the third quarter of 2010 was primarily attributable to the higher spend on research and development during the quarter.
Revenues for the reported quarter climbed 14% to $27.7 million, above the Zacks Consensus Estimate of $26 million.
Revenues were inclusive of $14 million from the company’s alliance with Roche (RHHBY), $5.6 million from Alnylam‘s partnership with Takeda Pharmaceuticals, in addition to $8.1 million of expense reimbursement and amortization revenues from Novartis (NVS), the National Institutes of Health, Cubist Pharmaceuticals Inc. (CBST) and Biogen Idec Inc. (BIIB) among others.
Research and development (R&D) costs climbed approximately 18.3% to $27.5 million. The rise was primarily attributable to costs incurred by the company arising from job-cuts announced in September 2010 following the end of its five-year agreement with Novartis. The increase also resulted from rise in costs associated with the increased R&D headcount and the company’s efforts to expand its pipeline.
General and administrative (G&A) expenses in the reported quarter fell 16.4% to $8.9 million. The decrease in G&A spend was primarily driven by lower professional service fees mainly for legal activities. Interest income at Alnylam fell 40% to $0.6 million in the third quarter of 2010. The reduction was primarily attributable to the significantly lower average interest rates coupled with lower average cash, cash equivalents and marketable securities balances in the reported quarter.
Alnylam exited the quarter with approximately $372 million in cash, cash equivalents and marketable securities and no debt, thereby providing the company with flexibility to invest in its pipeline and other avenues. Alnylam expects to end 2010 with a cash balance in excess of $325 million. We maintain our long-term neutral stance on the stock, which is supported by the Zacks #3 Rank (short-term Hold rating) currently carried by the company.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CUBIST PHARM (CBST): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
Zacks Investment Research
